This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

SciClone Pharmaceuticals, Inc. Is Being Investigated On Behalf Of Shareholders

SAN DIEGO, March 28, 2013 /PRNewswire/ --  Shareholder rights law firm Robbins Arroyo LLP is investigating whether officers and directors of SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) breached their fiduciary duties to shareholders. 


Robbins Arroyo LLP Investigates Potential Accounting Errors and Misstated Financial Results in SciClone's Previously Filed Financial Statements for 2011 and Most of 2012 

Robbins Arroyo LLP is investigating whether SciClone's financial reporting for fiscal years 2011 and 2012 may have been false and misleading.  After the market closed on February 22, 2013, SciClone announced that its previously issued financial statements for the fiscal year 2011 and the first three quarters of fiscal 2012, were unreliable and would be restated.  Specifically, the restatements will correct accounting errors in the company's recognition of product return reserves for sales of the drug Aggrastat and the timing of revenue recognition for certain products sold by SciClone's subsidiary NovaMed, a China-based company acquired in April 2011.  On news of the restatement, SciClone's stock declined approximately 9%, to close at $4.40 per share on February 25, 2013.      

In light of this news, Robbins Arroyo LLP is investigating whether: (i) SciClone's financial statements were not prepared in accordance with Generally Accepted Accounting Principles; and (ii) the company's internal accounting controls were deficient and permitted the premature recognition of revenue, leading to misstated financial results.  

Robbins Arroyo LLP highlights that SciClone shareholders have the option to pursue a shareholder derivative action through which shareholders aim to hold insider wrongdoers accountable for their actions, prevent future misconduct, and bring long-term value back to the company.  Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003,, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.  For more information, please go to  

Press release link:

Attorney Advertising. Past results do not guarantee a similar outcome.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,786.37 -12.12 -0.07%
S&P 500 2,088.59 -1.52 -0.07%
NASDAQ 5,119.2540 -8.2710 -0.16%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs